-
BioCryst Pharmaceuticals (BCRX) Q1 2024 Earnings Call Transcript
06 May 2024 18:05 GMT
… : The Motley Fool.
BioCryst Pharmaceuticals (BCRX 18.09%)
Q1 … advancing on schedule. Orladeyo revenue in Q1 exceeded our expectations … shipments were within 1% of fourth quarter 2023 paid shipments. This … to deliver an operating profit this year when excluding …
-
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET
06 May 2024 20:13 GMT
… development candidate in the fourth quarter and look forward … candidate in the fourth quarter of 2024 and … Tables to Follow
ENANTA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS … 2024
2023
2024
2023
Revenue
$
17,054
$
17 …
-
Lupin Q4 Results | Net profit jumps 52% to ₹359 crore, declares dividend of ₹8
06 May 2024 16:39 GMT
Drug maker Lupin Ltd on Monday (May … .
The company's revenue from operations increased 12% to … Also Read: Route Mobile Q4 Results | Net profit dips 9%, declares dividend … notable decline in Profit Before Tax (PBT) during the fourth quarter, primarily due …
-
Latest News | Lupin Q4 Net Profit Rises 52 Pc at Rs 359 Cr; Revenue at Rs 4,961 Cr
06 May 2024 17:05 GMT
…
The Mumbai-based drug maker reported a net profit of Rs 236 crore … and Other Important Instructions.
Total revenue from operations rose to Rs … strong set of numbers in Q4. Our US sales remain … resurgence for the company, the drugmaker looks forward to an even …
-
QuidelOrtho (QDEL) Securities Fraud Class Action Filed After QDEL Reports Disastrous Q4 2023 Results, Terminates CEO, Withdraws FDA Submission - Hagens Berman
06 May 2024 19:36 GMT
… maintain a stable high margin revenue stream from its respiratory … to its distributors and pharmacy chain customers than they … when QuidelOrtho announced disastrous Q4 and FY 2023 financial results … lower endemic COVID-19 revenues during the quarter from …
-
Lupin Q4 Results: Profit jumps 52% YoY to Rs 368 crore; revenue up 12%
06 May 2024 15:59 GMT
… the last year quarter.
Revenue from operations in the same … move forward with sustainable and profitable growth and delivered another … be the third largest pharmaceutical player in both the … Growth markets sales for the fourth quarter increased 16% YoY to Rs …
-
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript
06 May 2024 14:17 GMT
… Director, Investor Relations, Ascendis Pharma. Please go ahead. Tim … years to build out profitable and robust supply chains … SKYTROFA revenue increased 1% compared to the fourth quarter of 2023 … achondroplasia, both in the fourth quarter of 2024, and also …
-
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2024 Earnings Call Transcript
06 May 2024 14:16 GMT
… welcome to the Lexicon Pharmaceuticals First Quarter 2024 Financial Results … major payers to secure profitable and equitable access for … over 40% in Q1 versus Q4. While we continue to … , together with expected product revenues, will provide us with …
-
Lupin Q4 Results Preview: Net profit likely to more than double, margin may expand by 700 bps
06 May 2024 12:46 GMT
Lupin Q4 FY24 Results Preview: Mumbai-headquartered pharmaceutical company Lupin … 6. Analysts expect the drug maker to stage a strong … expect the pharma company's quarterly revenue to grow … of profitability, at 20 per cent for the fiscal fourth quarter, …
-
Dr Reddy's Q4 Preview: PAT may rise over 50% YoY on strong US sales
06 May 2024 09:57 GMT
Pharma major Dr Reddy's … post robust numbers in the fourth quarter ended March 2024, led by … consolidated net profit at Rs 1,379 crore, and revenue from operations … from Dr Reddy's Q4
Kotak Equities
We expect North …